Navigation Links
European young investigators network for Usher syndrome awarded E-Rare collab project
Date:11/13/2013

Based on a ranking list that was established by the EU Scientific Evaluation Committee, the E-Rare funding bodies recommended the European young investigators network for Usher syndrome (EUR-USH) coordinated by Dr. Kerstin Nagel-Wolfrum from Johannes Gutenberg University Mainz for funding. Out of 82 submitted projects, EUR-USH was among the 11 excellent scientific projects that were chosen after a competitive two-step scientific evaluation by peers. In October 2013, researchers held their kick-off meeting in Nijmegen, the Netherlands.

In addition to Johannes Gutenberg Mainz University, Germany, five other research institutions, namely AIBILI and IBILI in Coimbra, Portugal, INSERM institutes in Paris and Montpellier, France, and the Radboud UMC in Nijmegen, the Netherlands, will participate in the EUR-USH collaborative project. Financial support for the project will be provided by the national funding agencies, the German Federal Ministry of Education and Research (BMBF), the Portuguese Foundation for Science and Technology (FCT), the French National Research Agency (ANR), and the Netherlands Organisation for Health Research and Development (ZonMW).

In the EUR-USH network, young investigators with different backgrounds in science, clinical medicine, and genetic diagnostics synergize their expertise to shed more light upon the rare genetic disease Usher syndrome (USH). USH is the most common form of hereditary combined deaf-blindness in man. Since USH is genetically and clinically heterogeneous, diagnosing this disease is very challenging. So far the pathomechanisms resulting in the blindness of Usher patients are not fully understood. While the loss of hearing can currently be compensated by the use of cochlear implants, there is still no treatment for the associated blindness.

The EUR-USH project is divided into three components. The first component involves two Portuguese and two French work groups. Among their tasks are the improvement of Usher clinical diagnosis and the elaboration of significant markers for Usher disease progression. Results of the study will be uploaded into the newly established EUR-USH database. In the second segment, work groups in the Netherlands and Germany will concentrate on identifying the molecular pathogenesis of Usher syndrome. By applying proteomic and imaging approaches they aim to identify novel members of the USH interactome to unravel common cellular pathways in which USH proteins are involved and provide candidates or modifier genes for USH and related retinal degenerations. In the third segment, groups will be developing treatment methods for the ophthalmologic component of the disease. They will evaluate two different approaches, gene augmentation and translational read-though, to treat the progressive retinal degeneration of Usher syndrome patients.

The scientists hope that the interdisciplinary collaboration will help further understanding of the clinical, genetic, and molecular background of Usher syndrome and will provide a valuable contribution to possible treatment approaches. The primary objective of the European research team is to improve the quality of life for Usher patients.


'/>"/>

Contact: Dr. Kerstin Nagel-Wolfrum
nagelwol@uni-mainz.de
49-613-139-20131
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. An invasive Asian fly is taking over European fruit
3. Building the European Unions Natura 2000 -- the largest ever network of protected areas
4. European grasslands challenge rainforests as the most species-rich spaces on Earth
5. European mountain plant population shows delayed response to climate change
6. European Society of Human Reproduction and Embryology 28th Annual Meeting -- Istanbul
7. Citizen science helps unlock European genetic heritage
8. PETA files complaint with European ombudsman over animal testing for REACH
9. First Indian-European research networking projects in the social sciences launched
10. Ukraine to Introduce European Standard of Biometric ID
11. BiOptix to highlight new 404pi instrument at European symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
Breaking Biology Technology: